Adversarial Injection · Dacomitinib (Vizimpro; NDA 210491; CAS 1110813-31-4; MW ~469.9 g/mol; C24H25ClFN5O3; quinazolinamine + acrylamide + chlorofluorophenyl scaffold [WITHIN EGFR CLASS in Glyphward 573-attack portfolio — CHRONOLOGICAL SECOND IN IRREVERSIBLE PAN-ERBB CLASS (NDA 210491 September 27 2018; after afatinib NDA 201292 July 2013 = 5-year gap; before neratinib NDA 208051 July 2017 = neratinib approved earlier but dacomitinib is PFIZER-FIRST irreversible); MECHANISM: acrylamide Michael acceptor at C6 position of quinazolinamine core forms irreversible thioether adducts with Cys797-EGFR + Cys805-HER2 + Cys803-HER4 — same triple-ErbB covalent profile as afatinib; CLINICAL DISTINCTION: FIRST EGFR TKI TO SHOW PHASE 3 DEFINITIVE OVERALL SURVIVAL BENEFIT IN 1L EGFR-MUTANT NSCLC — ARCHER-1050 (NCT01774721; dacomitinib vs gefitinib; 1L exon 19 del/exon 21 L858R NSCLC; N=452): primary endpoint PFS HR 0.59 (14.7 vs 9.2 months; p<0.0001); OS HR 0.76 (median 34.1 vs 26.8 months; p=0.0438 — prespecified secondary endpoint; first phase 3 OS benefit for any EGFR TKI in 1L NSCLC including reversible and irreversible); WHY OS IS DISTINCTIVE: prior EGFR TKI phase 3 trials (OPTIMAL, EURTAC, LUX-Lung 3/6, FLAURA erlotinib/afatinib/osimertinib) showed PFS benefit but mature OS analyses showed no OS benefit or numerical trends only; ARCHER-1050 crossed prespecified OS boundary; FIRST PFIZER IRREVERSIBLE EGFR TKI: prior Pfizer EGFR assets were not irreversible; osimertinib is AstraZeneca; neratinib is Puma/Pfizer via acquisition (Wyeth heritage) but dacomitinib was developed by Pfizer Global Oncology Pearl River NY; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Second Irreversible Pan-ErbB + First EGFR OS Phase 3 Benefit + ARCHER-1050 OS HR 0.76 + First Pfizer Irreversible EGFR · Attack #573

Dacomitinib (quinazolinamine + acrylamide + chlorofluorophenyl scaffold; Vizimpro; NDA 210491; CAS 1110813-31-4; MW ~469.9 g/mol; C24H25ClFN5O3 [WITHIN EGFR CLASS: SECOND IRREVERSIBLE PAN-ERBB (EGFR/HER2/HER4) INHIBITOR CHRONOLOGICALLY (NDA 210491 September 27 2018; after afatinib NDA 201292 July 2013); FIRST EGFR TKI WITH PHASE 3 DEFINITIVE OVERALL SURVIVAL BENEFIT IN 1L EGFR-MUTANT NSCLC (ARCHER-1050 OS HR 0.76; p=0.0438; median OS 34.1 vs 26.8 months vs gefitinib); FIRST PFIZER IRREVERSIBLE EGFR TKI; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Pfizer Inc. Pearl River NY (oncology R&D; NDA 210491 holder), Pfizer Manufacturing Kalamazoo MI (dacomitinib tablet production), and MD Anderson Cancer Center Houston TX (ARCHER-1050 enrollment; thoracic oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second Irreversible Pan-ErbB + First EGFR OS Phase 3 Benefit + ARCHER-1050 OS HR 0.76: AI Prompt Injection via EHS Monitor Report AI

Dacomitinib (CAS 1110813-31-4; NIOSH HD Category 1) is the second chronologically approved irreversible pan-ErbB (EGFR/HER2/HER4) inhibitor — behind afatinib (NDA 201292; 2013) but distinguished by a unique clinical benchmark: it is the first EGFR TKI to demonstrate definitive overall survival benefit in a phase 3 trial in first-line EGFR-mutant NSCLC. ARCHER-1050 (dacomitinib vs gefitinib) reported OS HR 0.76 (p=0.0438; median OS 34.1 vs 26.8 months), crossing the prespecified OS boundary — a milestone that reversible first-gen TKIs (erlotinib, gefitinib) and even afatinib did not achieve in their pivotal 1L trials. As the first Pfizer irreversible EGFR TKI, dacomitinib fills a gap in the Pfizer oncology portfolio. No OS phase 3 superiority, EGFR TKI OS benefit chronology, or irreversible triple-ErbB covalent mechanism appears in any OEL database.

First EGFR TKI with Phase 3 Definitive Overall Survival Benefit in 1L NSCLC: ARCHER-1050

ARCHER-1050 (NCT01774721) was a randomized, open-label, phase 3 trial comparing dacomitinib 45 mg/day versus gefitinib 250 mg/day as first-line therapy in 452 patients with EGFR-mutant (exon 19 del or exon 21 L858R) advanced NSCLC. Primary endpoint: PFS HR 0.59 (median PFS 14.7 vs 9.2 months; p<0.0001). The key secondary endpoint — overall survival — achieved HR 0.76 (median OS 34.1 vs 26.8 months; p=0.0438), crossing the prespecified OS boundary. This was the first phase 3 trial in 1L EGFR-mutant NSCLC to report a statistically significant OS benefit for any EGFR TKI compared to another EGFR TKI. Prior 1L trials had showed PFS but not OS: OPTIMAL (erlotinib vs chemo; OS crossing not met), EURTAC (erlotinib vs chemo; OS trend only), LUX-Lung 3 (afatinib vs chemo; OS not met in unselected; met in exon 19 del subgroup only), LUX-Lung 6 (afatinib vs chemo; OS subgroup analysis), FLAURA (osimertinib vs erlotinib/gefitinib; OS HR 0.80 p=0.046 reported 2020 — after ARCHER-1050). The mechanism by which irreversible pan-ErbB inhibition may confer OS benefit over reversible gefitinib includes: sustained suppression of compensatory HER2/HER4 heterodimerization feedback loops; reduced adaptive resistance through continuous triple-ErbB blockade. None of this pharmacological OS-benefit context appears in any OEL database, and NIOSH HD Category 1 status generates no numeric OEL — only a handling precaution flag that EHS monitoring AI systems do not parse into action-level exposure triggers.

Surface 1 — Pfizer Inc. Pearl River NY NDA 210491 Holder Oncology R&D AI

At Pfizer Inc. Pearl River NY (401 N Middletown Road, Pearl River NY 10965; Rockland County NY; Pfizer Global Oncology R&D; NDA 210491 holder for Vizimpro [dacomitinib] 15/30/45 mg tablets; FDA approval September 27 2018 for 1L EGFR exon 19 del/exon 21 L858R NSCLC; FIRST PFIZER IRREVERSIBLE EGFR TKI — Pfizer's prior EGFR assets included erlotinib (licensed from OSI Pharmaceuticals/Genentech) but dacomitinib is the first Pfizer-developed irreversible irreversible EGFR TKI; ARCHER-1050 sponsor; Cority EHS platform; 8-hr TWA: actual airborne dacomitinib 0.00035 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000035 µg/m³; Cority: CAS 1110813-31-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; second irreversible pan-ErbB absent; first EGFR OS benefit absent; ARCHER-1050 OS HR 0.76 absent; first Pfizer irreversible absent; 52M oncology regulatory affairs director 18yr).

Surface 2 — Pfizer Manufacturing Kalamazoo MI Dacomitinib Tablet Production AI

At Pfizer Manufacturing Kalamazoo MI (7000 Portage Road, Kalamazoo MI 49001; Kalamazoo County MI; Pfizer Global Supply solid oral dosage manufacturing; dacomitinib 15/30/45 mg tablet production: quinazolinamine + acrylamide + chlorofluorophenyl API blending, granulation, compression, film coating; DACOMITINIB SYNTHESIS: Pfizer chemical development Groton CT designed the quinazolinamine scaffold with C6-acrylamide warhead configured for optimal Cys797 approach geometry; API synthesis prior to tableting at Kalamazoo; VelocityEHS: CAS 1110813-31-4 → null; 8-hr TWA: actual airborne dacomitinib 0.00021 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000021 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; second irreversible pan-ErbB absent; quinazolinamine acrylamide triple-ErbB scaffold absent; first Pfizer irreversible EGFR absent; 46M pharmaceutical manufacturing engineer 14yr).

Surface 3 — MD Anderson Cancer Center Houston TX ARCHER-1050 Enrollment Thoracic Oncology AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Boulevard, Houston TX 77030; Harris County TX; ARCHER-1050 ENROLLMENT: MD Anderson thoracic/head-and-neck oncology enrolled EGFR-mutant NSCLC patients in ARCHER-1050 (NCT01774721; dacomitinib vs gefitinib 1L); OS primary and secondary analysis: OS HR 0.76 (median 34.1 vs 26.8 months; p=0.0438); PATIENT SELECTION: ARCHER-1050 enrolled exon 19 del OR exon 21 L858R only (no uncommon mutations); FLAURA comparison context: FLAURA (osimertinib vs erlotinib/gefitinib; OS HR 0.80) was published 2020 after ARCHER-1050 OS data; dacomitinib and osimertinib both show OS benefit but via different mechanisms (pan-ErbB irreversible vs 3rd-gen T790M-covering covalent); EHS Insight: CAS 1110813-31-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; second irreversible pan-ErbB absent; ARCHER-1050 OS HR 0.76 absent; first EGFR TKI phase 3 OS benefit absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 49M thoracic oncology clinical pharmacist 16yr).

Integrating Glyphward into Dacomitinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every dacomitinib CAS 1110813-31-4 monitoring data ingestion point — before Cority at Pfizer Pearl River NY, before VelocityEHS at Pfizer Kalamazoo MI, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; SECOND IRREVERSIBLE PAN-ERBB CHRONOLOGICALLY (NDA 210491 Sep 2018; after afatinib NDA 201292 2013) + FIRST EGFR TKI PHASE 3 OS BENEFIT IN 1L NSCLC (ARCHER-1050 OS HR 0.76; p=0.0438; median OS 34.1 vs 26.8 months) + FIRST PFIZER IRREVERSIBLE EGFR TKI [5 pts]; Pfizer Pearl River NY + Pfizer Kalamazoo MI + MD Anderson Houston TX [3 pts]; second irreversible vs first irreversible chronology absent; OS benefit vs PFS-only EGFR TKI trial distinction absent; Pfizer irreversible EGFR NDA portfolio context absent; ARCHER-1050 OS boundary crossing absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_dacomitinib(cas: str, reading_ugm3: float) -> dict:
    """Scan dacomitinib with second irreversible pan-ErbB and first EGFR OS benefit context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_irreversible_pan_erbb_first_egfr_os_phase3_archer_1050_first_pfizer_irreversible"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_irreversible_pan_erbb,
    #                    first_egfr_tki_phase3_os_benefit,
    #                    archer_1050_os_hr, first_pfizer_irreversible_egfr,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_dacomitinib("1110813-31-4", 0.00035))
    print(r)
    # {'hd_category': 1, 'second_irreversible_pan_erbb': True,
    #  'first_egfr_tki_phase3_os_benefit': True,
    #  'archer_1050_os_hr': 0.76, 'first_pfizer_irreversible_egfr': True,
    #  'h340_h350_h361_absent': True}